

Breast Cancer

A study in T-DM1 for use in patients with breast cancer after chemotherapy

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Trial Status
Completed

Trial Runs In
0 Countries

Trial Identifier
NCT01196052

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.

F. Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT01196052
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 years and older

Healthy Volunteers
No